Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Independent Association of Serum Aldosterone Level with Metabolic Syndrome and Insulin Resistance in Korean Adults

  • Min, Se Hee (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Se-Hong (Department of Family Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine) ;
  • Jeong, In-Kyung (Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine) ;
  • Cho, Ho Chan (Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Jeong, Jin-Ok (Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine) ;
  • Lee, Ju-Hee (Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine) ;
  • Kang, Hyun-Jae (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Hyo Soo (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Park, Kyong Soo (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lim, Soo (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • Received : 2017.09.03
  • Accepted : 2017.11.21
  • Published : 2018.03.19
⟨ Previous Next ⟩

Abstract

Background and Objectives: A relationship between renin-angiotensin system (RAS) components and metabolic syndrome (MetS) has been suggested, but not elucidated clearly. We examined the levels of RAS components in patients with and without MetS and their association with MetS in Korean population. Methods: This study was approved by the review boards of the participating institutions and endorsed by the Korean Society of Lipid and Atherosclerosis. We screened 892 Koreans aged ${\geq}20years$ who underwent evaluation of hypertension, diabetes, or dyslipidemia at 6 tertiary hospitals in 2015-2016. After excluding patients who were taking diuretics, ${\beta}-blockers$, or RAS blockers, or suspected of primary aldosteronism, 829 individuals were enrolled. Anthropometric and biochemical parameters including aldosterone, plasma renin activity (PRA), and aldosterone-to-PRA ratio were evaluated. The homeostasis model assessment for insulin resistance (HOMA-IR) were used for evaluating insulin resistance. Results: The mean age of the participants was $52.8{\pm}12.8years$, 56.3% were male, and their mean systolic and diastolic blood pressures were $133.9{\pm}20.0$ and $81.2{\pm}14.6mmHg$, respectively. The levels of serum aldosterone, but not PRA, were significantly higher in subjects with MetS than in those without ($20.6{\pm}33.6$ vs. $15.3{\pm}12.2ng/dL$, p<0.05), and positively correlated with waist circumference, blood pressure, triglycerides, and glycated hemoglobin. The levels of aldosterone were independently associated with the number of MetS components and HOMA-IR after adjusting for conventional risk factors. Conclusion: Serum aldosterone levels were higher in Korean adults with MetS than in those without. This finding suggests that increased aldosterone level might be closely associated with insulin resistance.

Keywords

Acknowledgement

Supported by : Seoul National University Bundang Hospital

References

  1. Hong AR, Lim S. Clinical characteristics of metabolic syndrome in Korea, and its comparison with other Asian countries. J Diabetes Investig 2015;6:508-15. https://doi.org/10.1111/jdi.12313
  2. Kim CS, Ko SH, Kwon HS, et al. Prevalence, awareness, and management of obesity in Korea: data from the Korea National Health and Nutrition Examination Survey (1998-2011). Diabetes Metab J 2014;38:35-43. https://doi.org/10.4093/dmj.2014.38.1.35
  3. Stiefel P, Vallejo-Vaz AJ, García Morillo S, Villar J. Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011;2011:685238.
  4. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012;302:H1219-30. https://doi.org/10.1152/ajpheart.00796.2011
  5. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-73. https://doi.org/10.1056/NEJM198909283211305
  6. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6. https://doi.org/10.1016/S0140-6736(98)05012-0
  7. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001;286:1882-5. https://doi.org/10.1001/jama.286.15.1882
  8. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 2017;40:S11-24. https://doi.org/10.2337/dc17-S005
  9. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. https://doi.org/10.1001/jama.289.19.2560
  10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
  11. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011;9:48. https://doi.org/10.1186/1741-7015-9-48
  12. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
  13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. https://doi.org/10.1007/BF00280883
  14. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10. https://doi.org/10.1210/jcem.85.7.6661
  15. Patel VB, Parajuli N, Oudit GY. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin Sci (Lond) 2014;126:471-82. https://doi.org/10.1042/CS20130344
  16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62. https://doi.org/10.1056/NEJM199311113292004
  17. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. https://doi.org/10.1056/NEJMoa011161
  18. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41. https://doi.org/10.1056/NEJMoa033263
  19. Rossi GP, Belfiore A, Bernini G, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008;93:2566-71. https://doi.org/10.1210/jc.2008-0251
  20. Bentley-Lewis R, Adler GK, Perlstein T, et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007;92:4472-5. https://doi.org/10.1210/jc.2007-1088
  21. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011;13:163-72. https://doi.org/10.1007/s11906-011-0182-2
  22. Jeon JH, Kim KY, Kim JH, et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008;22:1502-11. https://doi.org/10.1096/fj.07-9412com
  23. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007;30:2349-54. https://doi.org/10.2337/dc07-0525
  24. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007;49:704-11. https://doi.org/10.1161/01.HYP.0000253258.36141.c7
  25. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010;95:1986-90. https://doi.org/10.1210/jc.2009-2521
  26. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457-63. https://doi.org/10.1210/jc.2006-0736
  27. Fallo F, Federspil G, Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Hypertens Rep 2007;9:106-11. https://doi.org/10.1007/s11906-007-0019-1
  28. Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995;25:30-6. https://doi.org/10.1161/01.HYP.25.1.30
  29. Kathiresan S, Larson MG, Benjamin EJ, et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005;18:657-65. https://doi.org/10.1016/j.amjhyper.2004.12.005
  30. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007;116:984-92. https://doi.org/10.1161/CIRCULATIONAHA.107.708537

Cited by

  1. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease vol.8, pp.3, 2018, https://doi.org/10.3390/biom8030096
  2. Predictive value of heart rate deceleration capacity on coronary artery lesion in acute phase of Kawasaki disease vol.10, pp.None, 2020, https://doi.org/10.1038/s41598-020-67121-3
  3. Higher prevalence of metabolic disorders in patients with bilateral primary aldosteronism than unilateral primary aldosteronism vol.94, pp.1, 2018, https://doi.org/10.1111/cen.14318
  4. Relationship of plasma aldosterone levels and carbohydrate metabolism in heart failure with preserved ejection fraction vol.26, pp.1, 2021, https://doi.org/10.15829/1560-4071-2021-3991